Circulating tumor DNA as liquid biopsy in lung cancer: Biological characteristics and clinical integration
C Li, J Shao, P Li, J Feng, J Li, C Wang - Cancer Letters, 2023 - Elsevier
Lung cancer maintains a high morbidity and mortality rate globally despite significant
advancements in detection and therapy in the era of precision medicine. Excisional biopsy …
advancements in detection and therapy in the era of precision medicine. Excisional biopsy …
[HTML][HTML] Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer
R Condorelli, L Spring, J O'shaughnessy, L Lacroix… - Annals of …, 2018 - Elsevier
Background While deregulation of the cyclin D1-CDK4/6-retinoblastoma pathway is
common in hormone receptor positive (HR+) breast cancer, Rb is usually intact in HR+ …
common in hormone receptor positive (HR+) breast cancer, Rb is usually intact in HR+ …
[HTML][HTML] Liquid biopsy prediction of axillary lymph node metastasis, cancer recurrence, and patient survival in breast cancer: A meta-analysis
JH Lee, H Jeong, JW Choi, HE Oh, YS Kim - Medicine, 2018 - journals.lww.com
Background: Liquid biopsies using circulating tumor DNA (ctDNA) and cell-free DNA
(cfDNA) have been developed for early cancer detection and patient monitoring. To …
(cfDNA) have been developed for early cancer detection and patient monitoring. To …
[HTML][HTML] Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment
AR Thierry, S El Messaoudi, C Mollevi, JL Raoul… - Annals of …, 2017 - Elsevier
Background While tumor-tissue remains the 'gold standard'for genetic analysis in cancer
patients, it is challenged with the advent of circulating cell-free tumor DNA (ctDNA) analysis …
patients, it is challenged with the advent of circulating cell-free tumor DNA (ctDNA) analysis …
Monitoring tumor burden in response to FOLFIRINOX chemotherapy via profiling circulating cell-free DNA in pancreatic cancer
We aimed to explore the application of circulating cell-free DNA (cfDNA) profiling in
monitoring tumor burden in patients with pancreatic ductal adenocarcinoma (PDAC). Thirty …
monitoring tumor burden in patients with pancreatic ductal adenocarcinoma (PDAC). Thirty …
Development and validation of an ultradeep next-generation sequencing assay for testing of plasma cell-free DNA from patients with advanced cancer
F Janku, S Zhang, J Waters, L Liu, HJ Huang… - Clinical Cancer …, 2017 - AACR
Purpose: Tumor-derived cell-free DNA (cfDNA) in plasma can be used for molecular testing
and provide an attractive alternative to tumor tissue. Commonly used PCR-based …
and provide an attractive alternative to tumor tissue. Commonly used PCR-based …
Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing
Abstract Purpose BRCA1 and BRCA2 (BRCA1/2) are two major high-penetrance breast
cancer predisposition genes, mutations in which can lead to high risks and early onset of …
cancer predisposition genes, mutations in which can lead to high risks and early onset of …
Structural snapshots of RAF kinase interactions
S Rezaei Adariani, M Buchholzer… - Biochemical Society …, 2018 - portlandpress.com
RAF (rapidly accelerated fibrosarcoma) Ser/Thr kinases (ARAF, BRAF, and CRAF) link the
RAS (rat sarcoma) protein family with the MAPK (mitogen-activated protein kinase) pathway …
RAS (rat sarcoma) protein family with the MAPK (mitogen-activated protein kinase) pathway …
A modified ficoll-paque gradient method for isolating mononuclear cells from the peripheral and umbilical cord blood of humans for biobanks and clinical laboratories
Y Jia, H Xu, Y Li, C Wei, R Guo, F Wang… - Biopreservation and …, 2018 - liebertpub.com
Although the Ficoll-Paque method is classically used to isolate peripheral blood
mononuclear cells (PBMCs), modifications in this method are required for a more rapid and …
mononuclear cells (PBMCs), modifications in this method are required for a more rapid and …
[HTML][HTML] Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors
A suitable clinical-grade platform is required for detection of somatic mutations with high
sensitivity in cell-free DNA (cfDNA) of patients with solid tumors. In this study, we evaluated …
sensitivity in cell-free DNA (cfDNA) of patients with solid tumors. In this study, we evaluated …